Advanced Search

Technical Analysis for SWTX - SpringWorks Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 33.15 0.94% 0.31
SWTX closed up 0.94 percent on Friday, February 21, 2020, on 37 percent of normal volume.
1 Watcher
Watchlist Portfolio

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Up
Historical SWTX trend table...
Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
20 DMA Resistance Bearish 0.94%
NR7 Range Contraction 0.94%
NR7-2 Range Contraction 0.94%
20 DMA Resistance Bearish 0.97%
50 DMA Resistance Bearish 0.97%
NR7 Range Contraction 0.97%
20 DMA Resistance Bearish -0.36%
50 DMA Resistance Bearish -0.36%
Pocket Pivot Bullish Swing Setup -0.36%
Older EOD signals for SWTX ...
View Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
SWTX Chart by TradingView
Basic chart:

Profile

Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm's products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.
Biotechnology Biopharmaceutical Cancer Life Sciences Pharmaceutical Industry Pharmacy Drug Development

Is SWTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Feb 18 SpringWorks Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference
Jan 13 Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma
Jan 6 SpringWorks Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Dec 24 The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict
Dec 18 The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data
Dec 16 Hedge Funds Have Never Been This Bullish On SpringWorks Therapeutics, Inc. (SWTX)
Dec 13 We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Dec 10 The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares
Dec 9 Researchers Present Preclinical Data Showing Synergistic Activity of SpringWorks Therapeutics’ Gamma Secretase Inhibitor (Nirogacestat) with GlaxoSmithKline’s BCMA Antibody-Drug Conjugate (Belantamab Mafodotin) at the American Society of Hematology (AS...
Dec 4 Raymond James likes Zimmer Biomet in premarket analyst action
See more SWTX news...

Indicators

Indicator Value
52 Week High 40.5
52 Week Low 17.02
Average Volume 132,160
200-Day Moving Average 0.00
50-Day Moving Average 34.15
20-Day Moving Average 33.36
10-Day Moving Average 32.31
Average True Range 2.34
ADX 13.64
+DI 17.27
-DI 13.39
Chandelier Exit (Long, 3 ATRs ) 31.88
Chandelier Exit (Short, 3 ATRs ) 36.42
Upper Bollinger Band 36.92
Lower Bollinger Band 29.81
Percent B (%b) 0.47
BandWidth 21.31
MACD Line -0.37
MACD Signal Line -0.33
MACD Histogram -0.0397
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 34.98
Resistance 3 (R3) 35.06 34.52 34.68
Resistance 2 (R2) 34.52 34.06 34.49 34.57
Resistance 1 (R1) 33.84 33.77 34.18 33.76 34.47
Pivot Point 33.30 33.30 33.48 33.27 33.30
Support 1 (S1) 32.62 32.84 32.96 32.54 31.83
Support 2 (S2) 32.08 32.55 32.05 31.73
Support 3 (S3) 31.40 32.08 31.63
Support 4 (S4) 31.32